-
The prospects and ethics of CRISPR/Cas gene editing therapy are disputed
Time of Update: 2020-12-23
Cas can be used to program the cutting and editing of DNA sequences Source: Science Followed, with the joint efforts of Dudner, Carpentier and other scientists, CRISPR/Cas9 gene editing tools became increasingly perfect, becoming the absolute star of gene editing, sweeping the entire life sciences like a "storm." Scientists, you followed me in using CRISPR/Cas technology to genetically edit bacteria, fungi, plants, animals, including human cells and embryos, the hottest of which is gene editing therapy.
-
Menstruation does not adjust for two years, cancer has changed, regret not doing this!
Time of Update: 2020-12-23
For the first time, refusing laparoscopy at the end of 2018, the girl came to see a doctor because of a menstrual disorder, and the doctor gave her a B-super.
-
Cancer Research: More than 250,000 people have studied data showing that oral contraceptives can prevent ovarian and endometrial cancers
Time of Update: 2020-12-22
study, researchers looked at the short- and long-term relationship between oral contraceptives and breast, ovarian and endometrial cancers in more than 250,000 people.
even 30-35 years after the drug was stopped, the pill still protects against ovarian and endometrial cancers.
-
What's missing from the early diagnosis and treatment of breast tumors in county hospitals? The big currymen came to do this in person
Time of Update: 2020-12-22
(Health Times reporter Wei Wei) On a Saturday morning at the end of November, more than 100 women of different ages arrived at the Miao Autonomous County People's Hospital in Qiong Zhongli, central H
-
Euro Radio: A new review of assessing pancreatic lesions using imaging histology
Time of Update: 2020-12-22
applications of imaging histology include the identification and diagnosis of various types of lesions of the bureau (n s 19), the classification of pancreatic disease (n s 23), and the prediction of prognostic or therapeutic response (n s 30).
-
12 hours after the tumor was cut? Xiangya Hospital's world's first robot and day surgery to remove the tumor
Time of Update: 2020-12-22
11 at 12 noon, Professor Zhang Chunfang led the surgical team to operate the surgical robot for Mr. Huang to remove the lower left lung back section of a 2cm×1.8cm size lump, considering benign tumors, the whole operation only took 10 minutes, the patient recovered well after surgery.
-
Euro Radio: Use CT texture analysis to discover the post-treatment response to liver cell liver cancer TACE!
Time of Update: 2020-12-22
Objective: To study the feasibility of accurately predicting the response of liver cancer to transductive arterial chemotherapy embolism (TACE) based on the nested multiparase decision tree model based on tumor size and pre-treatment CT texture parameters.
-
"CSCO- Redding Clinical Tumor New Progress Summit Forum" held, the big curry theory of drug innovation
Time of Update: 2020-12-22
Chinese Academy of Sciences academician, major new drug creation of the country's major science and technology special technical deputy general division Chen Kai first pointed out at the forum, since the implementation of the special, there have been nearly 60 new drugs of the first class approved, to fill the relevant disease areas of drug use gaps, to solve the people's major disease drug demand, alleviate the people's "expensive to see a doctor" problem provides a strong support.
-
China's first "antibody drug coupled treatment of malignant tumor clinical application expert consensus" released
Time of Update: 2020-12-22
On December 5, China's first "Expert Consensus on Clinical Application of Antibody Drug Associations for the Treatment of Malignant Tumors" was released at the "National Cancer Center Clinical Researc
-
Glutamate synapses bioelectrically into glioma cells to drive tumor progression
Time of Update: 2020-12-21
In addition, the researchers found that spontaneous slow intronate currents (slow inward currents, SICs) were present in fresh brain tissue smears of GBM cells and neuron co-culture and heterogeneity transplant models; known calcium ion signal is the communication center within the glioma.
-
Science and Cell Sub-Journal: Developing "smart" cell therapies for cancer with big data
Time of Update: 2020-12-21
In a second paper, published in the November 27, 2020 issue of Science, entitled "Precise T cell system programs designed by transcriptionally linking multiple receptors," Lim and his colleagues then demonstrated how these calculated protein data can be used to drive the design of effective and highly selective cancer cell therapies.
-
New first-line treatment for lung cancer (NSCLC)! 2 immunotherapy (Opdivo and Yervoy) are approved in Japan!
Time of Update: 2020-12-21
Nov 29, 2020 // -- Ono Pharmaceuticals and Bristol-Myers Squibb K.K., the Japanese subsidiary, recently jointly announced the anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, Navuliyu monotherapy) and anti-CTLA-4 therapy Yer Voy (ipilimumab, iplimumab) has been approved in Japan for first-line treatment of non-excisible advanced or relapsed non-small cell lung cancer (NSCLC) patients, including: (1) Opdivo-Yervoy programme; these approvals are based on data from two Phase 3 clinical studies conducted by Ono Pharmaceuticals and Shishi Shiguibo.
-
Latest Research Advances in CAR-T Cell Therapy (No. 18)
Time of Update: 2020-12-21
these new findings suggest that radiotherapy appears to be a safe treatment option before patients receive CAR-T cell infusions, which provides more support for future studies that combine radiotherapy with cell therapy.
-
Glutamine has a small molecular weight, but it has a lot of function
Time of Update: 2020-12-21
4.Science: Glutamine Blocking Drug Enhances Anti-Tumor Response, Expected to Be Used in CAR-T Cell Therapy doi:1 0.1126/science.aav2588 In a new study, researchers at Johns Hopkins University in the United States found that they developed a compound that blocks glutamine metabolism that slows tumor growth, alters tumor microenvironments, and promotes the production of persistent highly active anti-tumor T cells.
-
Interpretation! Scientists have developed a safer and more targeted way to transport CRISPR gene therapy!
Time of Update: 2020-12-21
In a study published in Interfaces entitled "Spatial and Temporal Control of CRISPR-Cas9-Mediated Gene Editing Delivered via a Light-Triggered Liposome System", scientists from the University of New South Wales and others have revealed a safe and more targeted way to transport CRISPR gene therapy, which researchers say can help transport CRISPR gene therapy, and is safer and more direct than current methods.
-
Nat Cell Biol: How do cancer cells protect themselves from harm?
Time of Update: 2020-12-20
researcher Professor Noa Lamm said: 'In this study, we shed light on the new molecular mechanisms by which cancer cells repair and replicate DNA, and we spent more than four years revealing new features of actoprotein, a special protein that interacts with myoprotein, which helps muscles contract, while actoprotein also forms a "cable" structure within the cell that functions like a building beam, helping to shape and shape cells.
-
Brain metastasis tumor SRS after in-place recurrence again the effect of SRS treatment
Time of Update: 2020-12-20
included in the standard: original literature published in English, treatment results reviewed by peers, the study of patients with cerebral metastasis tumor SRS in-place recurrence, the treatment method is SRS again.
-
Nat Cancer: Combine CAR-T cell therapy with special inhibitor drugs or hopefully treat multiple types of cancer!
Time of Update: 2020-12-20
'According to our results, this study is the first to reveal how the entire angioentic microenvironment can be reprogrammed with PAK3 inhibitors to promote and improve cell therapy for cancer, and importantly, this treatment may not be limited to brain tumors, which can also be used to treat other types of cancer, such as breast and pancreatic cancer, because vascular abnormalities are common to almost every solid tumor,' said Fan, a researcher.
-
Devel Cell: Why aren't some tumors responding to therapy? The culprit is: fibroblasts!
Time of Update: 2020-12-20
4, 2020 /PRY/ -- In a recent study published in the international journal Developmental Cell, scientists from the Sanford Burnham Prebys Institute for Medical Discovery and others said molecular chang
-
ASH2020: Clinical trials have shown that CAR-T cell therapy is highly effective in treating advanced non-Hodgkin's lymphoma
Time of Update: 2020-12-19
December 7, 2020 /--- Researchers at the Dana-Farber Cancer Institute in the United States reported at the 62nd annual meeting of the American Society of Hematology (ASH) that in a Phase 2 clinical trial, nearly 80 percent of patients with advanced non-Hodgkin's lymphoma (NHL) had reduced levels of cancer cells that could not be detected.
